Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Qiagen (QGEN) Cash & Equivalents (2016 - 2025)

Qiagen (QGEN) has disclosed Cash & Equivalents for 17 consecutive years, with $839.0 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 26.44% to $839.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $839.0 million through Dec 2025, up 26.44% year-over-year, with the annual reading at $839.0 million for FY2025, 26.44% up from the prior year.
  • Cash & Equivalents hit $839.0 million in Q4 2025 for Qiagen, up from $663.6 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $880.5 million in Q4 2021 to a low of $663.6 million in Q4 2024.
  • Historically, Cash & Equivalents has averaged $756.4 million across 5 years, with a median of $730.7 million in 2022.
  • Biggest five-year swings in Cash & Equivalents: skyrocketed 47.25% in 2021 and later fell 17.02% in 2022.
  • Year by year, Cash & Equivalents stood at $880.5 million in 2021, then decreased by 17.02% to $730.7 million in 2022, then dropped by 8.57% to $668.1 million in 2023, then fell by 0.68% to $663.6 million in 2024, then increased by 26.44% to $839.0 million in 2025.
  • Business Quant data shows Cash & Equivalents for QGEN at $839.0 million in Q4 2025, $663.6 million in Q4 2024, and $668.1 million in Q4 2023.